CombiMatrix Corporation Completes Sale to Invitae Corporation

Stradling represented CombiMatrix Corporation with its $34.9 million sale to Invitae Corporation (NYSE:NVTA), one of the fastest growing genetic information companies. 

CombiMatrix specializes in pre-implantation genetic diagnostics and screening, prenatal diagnosis, miscarriage analysis and pediatric developmental disorders, offering DNA-based testing for the detection of genetic abnormalities beyond what can be identified through traditional methodologies.